Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

NCT03900429 is registered in ClinicalTrials.gov with Madrigal Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03900429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03900429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 28, 2019
Completion date
January 31, 2028
Enrollment
1,759 (actual)
Sites
247

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis